Large number of real world evidence studies confirmed effectiveness and safety in treatment with Val/Aml and Val/Aml/HCT worldwide across various ethical groups, disease severities and co-morbidities
27 August 2017 (08:30 - 12:30)
Organised by:
Abstract
Slides
About the speaker
Novartis Pharma, Basel (Switzerland)
6 More presentations in this session
Access the full session
The Event
ESC Congress 2017
27 August 2017
08:30 CET
You may be interested in
Congress Presentation
